Advanced

Amyloid blood biomarker detects Alzheimer's disease

Nabers, Andreas; Perna, Laura; Lange, Julia; Mons, Ute; Schartner, Jonas; Güldenhaupt, Jörn; Saum, Kai Uwe; Janelidze, Shorena LU ; Holleczek, Bernd and Rujescu, Dan, et al. (2018) In EMBO Molecular Medicine 10(5).
Abstract

Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid-β (Aβ) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross-sectional BioFINDER cohort. In a further population-based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis... (More)

Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid-β (Aβ) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross-sectional BioFINDER cohort. In a further population-based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease diagnosis, Amyloid-β in blood plasma, BioFINDER, ESTHER, Immuno-infrared-sensor
in
EMBO Molecular Medicine
volume
10
issue
5
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • scopus:85044964738
ISSN
1757-4676
DOI
10.15252/emmm.201708763
language
English
LU publication?
yes
id
15923dd6-ea3c-4696-82c2-64c534c1a095
date added to LUP
2018-04-20 15:45:05
date last changed
2019-01-14 18:18:00
@article{15923dd6-ea3c-4696-82c2-64c534c1a095,
  abstract     = {<p>Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid-β (Aβ) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross-sectional BioFINDER cohort. In a further population-based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests.</p>},
  articleno    = {e8763},
  author       = {Nabers, Andreas and Perna, Laura and Lange, Julia and Mons, Ute and Schartner, Jonas and Güldenhaupt, Jörn and Saum, Kai Uwe and Janelidze, Shorena and Holleczek, Bernd and Rujescu, Dan and Hansson, Oskar and Gerwert, Klaus and Brenner, Hermann},
  issn         = {1757-4676},
  keyword      = {Alzheimer's disease diagnosis,Amyloid-β in blood plasma,BioFINDER,ESTHER,Immuno-infrared-sensor},
  language     = {eng},
  month        = {01},
  number       = {5},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {EMBO Molecular Medicine},
  title        = {Amyloid blood biomarker detects Alzheimer's disease},
  url          = {http://dx.doi.org/10.15252/emmm.201708763},
  volume       = {10},
  year         = {2018},
}